enGene (NASDAQ:ENGN) Upgraded to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of enGene (NASDAQ:ENGN) to a strong-buy rating in a research note released on Tuesday morning,Zacks reports.

Several other equities analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of enGene in a report on Tuesday, September 8th. Morgan Stanley downgraded enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a report on Thursday, June 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. Citigroup restated a “market perform” rating on shares of enGene in a research report on Wednesday, September 9th. Finally, Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $11.05.

enGene Trading Down 4.1%

NASDAQ ENGN opened at $1.63 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.21 and a current ratio of 10.21. enGene has a one year low of $1.40 and a one year high of $12.25. The company has a 50-day simple moving average of $1.84 and a 200-day simple moving average of $2.90. The firm has a market capitalization of $109.24 million, a PE ratio of -1.44 and a beta of -0.29.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04). On average, equities analysts forecast that enGene will post -1.81 earnings per share for the current year.

Institutional Trading of enGene

Several hedge funds have recently bought and sold shares of ENGN. Monashee Investment Management LLC raised its stake in shares of enGene by 8.5% during the first quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock valued at $2,179,000 after purchasing an additional 25,000 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in enGene in the first quarter worth about $251,000. Eversept Partners LP lifted its holdings in enGene by 12.0% in the first quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock worth $3,477,000 after purchasing an additional 54,708 shares during the period. Sei Investments Co. bought a new position in enGene in the 1st quarter valued at about $409,000. Finally, Renaissance Technologies LLC grew its position in enGene by 651.1% in the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock valued at $1,063,000 after buying an additional 135,318 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors.

Key enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Analysts cited in the report have an average price target of $11.05 for enGene, substantially above the recent trading level. This suggests significant potential upside if the company executes on its development plans and investor sentiment improves. enGene Holdings Inc. Stock Has Average Target Price of $11.05
• Neutral Sentiment: The article does not identify a new clinical, regulatory, or financial catalyst. As a result, the analyst target alone may have limited immediate influence on trading, particularly given enGene’s early-stage biotechnology profile.
• Negative Sentiment: Recent investor concerns include enGene’s quarterly earnings miss, with reported loss per share of $0.47 versus the $0.43 consensus estimate, as well as continued losses expected for the full year. The shares remain below their 50-day and 200-day moving averages, indicating persistent downward momentum despite the high analyst target.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.